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Abstract Interferon regulatory factor 1 (IRF-1) is an essential 
factor involved in the regulation of type I interferon (IFN) and 
IFN-inducible genes. The protein consists of 329 amino acids 
that are highly conserved from mouse to human. Similar to other 
transcription factors, the protein is modular in nature with a 
basic N-terminal region involved in DNA binding and an acidic 
C-terminal region required for activation. We report here the 
expression, purification and co-crystallization of the minimal N- 
terminal region of IRF-1 involved in DNA binding (amino acids 
1-113) with a 13 bp DNA fragment from the IFN-~ promoter. 
The crystals diffract to at least 3.0 A in resolution and belong to 
space group R3 with unit cell parameters of a = b = 84.8 A, 
c = 203.7 A. 
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1. Introduction 
Upon viral infection, a cascade of signal transduct ion mech- 
anisms is set in motion in the cell that ultimately bring about 
the product ion of type I interferon molecules (IFN-c~ and 
IFN-[3). Regulat ion of this process at the transcriptional level 
is modulated by a panoply of protein factors that bind to their 
promoter/enhancer sites and act in a concerted mode to acti- 
vate or repress gene expression [1,2]. Interferon regulatory 
factor 1 ( IRF- I )  is an essential player in the activation of 
type I IFN genes and several IFN-inducible genes [1,2]. 
More recently, IRF-1 has been shown to be involved in proc- 
esses such as cell growth, apoptosis, regulation of the nitric 
oxide synthase (iNOS) gene, and resistance to bacterial infec- 
tion [3-6]. Molecular cloning and mutat ional  analysis of IRF-  
1 have shown that the N-terminal region is responsible for 
DNA binding while the acidic C-terminal region is required 
for activation [7]. Sequence homology analysis reveals that 
IRF-1 belongs to a family of IFN regulatory factors that 
includes IRF-2 [8], and the transcription factors ISGF3-y 
and ICSBP that are involved in the JAK/STAT signalling 
pathway [9,10]. IRF-1 and IRF-2 compete for the same 
DNA sites (PRDI  and PRDI I I )  on the IFN-[3 promoter,  
with IRF- I  acting as a transcriptional activator and IRF-2 
acting as a transcriptional repressor [11]. To date, the only 
structural infi)rmation relevant to IRF-1 is the secondary 
structure assignment of IRF-2 by NMR [12]. Here we report 
the first co-crystals of a member of the IRF- I  family and its 
target DNA site. 
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2. Materials and methods 
We first undertook a proteolytic study to characterize the DNA 
binding domain of IRF-I. Partially purified recombinant full-length 
IRF-1 was digested with the non-specific protease papain. A time- 
course reaction was carried out at room temperature with two differ- 
ent IRF-1/papain ratios. A stable domain of ~ 14 kDa was found to 
be the predominant species in the digestion reaction. Gel retardation 
analysis howed that this fragment bound to DNA as equally well as 
the intact protein. The proteolytic fragment was purified by gel filtra- 
tion (Superdex 75) and subjected to NH2-terminal sequencing and 
mass spectrometry. Results showed that the proteolytic fragment en- 
compassed the region between amino acids 6 114. Based on these 
results, we subcloned the IRF-I DNA-binding region (amino acids 
1 113) into the vector pET-3a (Novagen) and expressed it in E. eoli 
as follows: A colony of BL21(DE3) pLysS b2 coli cells freshly trans- 
formed with the plasmid pET-31RFI was used to inoculate 20 ml of 
2×YT media containing 200 gg/ml of ampicillin. The cells were 
grown overnight at 37°C, and a 2 ml aliquot of the culture was 
used to inoculate 1 1 of 2 x YT media containing 200 mg of ampicillin. 
Cells were grown at 37°C to an OD~{~ of 0.6 and then induced with 
the addition of IPTG to a final concentration of 0.4 mM. After 4 h, 
the cells were harvested by centrifugation at 5000 rpm for 10 min and 
stored at -70°C. The protein expresses mostly in inclusion bodies. 
To purify the protein, frozen cells from the 1 1 culture were resus- 
pended in 150 ml of buffer HK500 (50 mM HEPES, pH 7.5, 500 mM 
KC1. 10% glycerol) containing 0.1% NP40, 1 mM EDTA, and 0.2 mM 
PMSF. The suspension was sonicated for 2 rain and then centrifuged 
for 40 rain at 15 000 rpm. The insoluble fraction containing IRF-I(I 
1131 was washed thoroughly by four consecutive cycles of resuspen- 
sion in HK500, sonication, and centrifugation (15 min at 15 000 rpm). 
After the final centrifugation the pellet was solubilized in buffer G (6 
M guanidine hydrochloride (Gu.HCL), 50 mM HEPES, 500 mM 
KCI, 10 mM DTT) and dialyzed for 12 h against each of the following 
solutions: HK500 + 2 M Gu-HCL, HK500 + 1 MGu'HCL, HK500 + 
0.5 M Gu'HCI. Final dialysis was against HK500 containing 10 mM 
DTT. The protein was ~90% pure at this stage. For the final puri- 
fication, the protein was concentrated down to 10 ml and loaded onto 
a Superdex 75 column previously equilibrated with buffer HAA500 
(50 mM HEPES, 500 mM ammonium acetate, 10% glycerol, 10 mM 
DTT, pH 6.5). A single liter of bacterial cells yielded ~ 40 mg of pure 
protein. The DNA-binding activity of the refolded protein was com- 
parable to that of the native protein. For crystallization the protein 
was concentrated to 10 13 mg/ml by ultrafiltration (Amicon), ali- 
quoted, and stored at 70°C. 
3. Results and discussion 
For co-crystall ization studies, we synthesized and purified a 
series of DNA fragments (10-18 bp) based on the PRDI  se- 
quence from the IFN-[3 promoter.  Of  these, only the blunt- 
ended 13-mer containing the exact PRDI  sequence was found 
5 ' -GAGAAGTGAAAGT-  3 ' 
3 ' -CTCTTCACTTTCA-  5 ' 
Fig. I. The 13-mer oligomer used in IRF-1/DNA co-crystallization. 
The sequence matches the PRDI site from the 1FN-[3 promoter. 
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Fig. 2. A: A co-crystal measuring ~0.4x0.3x0.1 mm of IRF-I/ 
PRDI complex. B: Diffraction from a frozen co-crystal recorded 
with a Rigaku RU200 rotating anode X-ray generator. The image 
corresponds to a 2 ° oscillation and shows diffraction to at least 3 A 
resolution. The streaks corresponding to 'DNA reflections' can be 
seen in the picture. 
to produce co-crystals (Fig. 1). Initial co-crystallization trials 
were performed by the sparse matrix method [13], using hang- 
ing drops. Co-crystallization trials at room temperature pro- 
duced only microcrystals. However, at 4°C we were able to 
identify conditions that yielded large needles. These condi- 
tions were eventually refined to produce large, chunky co- 
crystals, measuring up to 0 .4x0.3x0.1 mm (Fig. 2A). The 
best co-crystals begin to appear after a few hours and grow 
to a full size within 3 days from 18 to 22% polyethylene 
glycol 8000 (PEG 8K) solutions containing 300 mM ammo- 
nium acetate (pH 6.5). The presence of protein and DNA in 
the co-crystals was confirmed by gel electrophoresis. For dif- 
fraction analysis, the co-crystals were transferred in a stepwise 
manner (using 5% glycerol increments) to a final cryoprotec- 
tant solution containing 25% PEG 8K, 20% glycerol, and 300 
mM ammonium acetate. 
The co-crystals diffract to 3.0 ~, resolution on an R-axis II 
imaging plate area detector mounted on a Rigaku rotating 
anode X-ray source (100 mA and 50 kV) (Fig. 2B). Using 
the HKL programs (HKL Research), the co-crystals were 
found to belong to space group R3 with unit cell dimensions 
of a = 84.8 A, b = 84.8 A, c = 203.7 A, c~=90 °, 13=90 °, T = 120 °. 
Surprisingly, synchrotron radiation did not extend the resolu- 
tion of the co-crystals. Assuming a model in which one IRF-1 
molecule is bound to the 13-bp DNA fragment, a Vm calcu- 
lation suggests that there are two such complexes in the cr),s- 
tallographic asymmetric unit. This gives a Vm value, 3.3 A3/ 
Da, which is within the range of values, 1.68-3.53 A3/Da, 
observed with protein crystals [14,15]. We also measured mul- 
tiwavelength anomalous diffraction (MAD) data from a bro- 
minated derivative of the IRF-1/PRDI complex. The deriva- 
tive was prepared by substituting bromouracils for five 
thymine residues within the PRDI sequence. The MAD data 
were measured from a single frozen cocrystal (-162°C) at 
Cornell High Energy Synchrotron Source (CHESS). The 
data were recorded using the 2k×2k charge coupled device 
(CCD) detector at beamline F2. The MAD data are 99% com- 
plete to 3 ,~ resolution and have R~y .... in the range of 6.1- 
6.9%. The structure of IRF-1/DNA complex promises to pro- 
vide a framework for understanding how IRF-1 family mem- 
bers recognize DNA in order to regulate the interferon system. 
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